Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% β-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In at least one embodiment, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.

The present invention relates to a lipoteichoic acid isolated from Bifidobacteria cultured in excess of glucose which has fat reduction activity, thus being useful for exploitation in the following application areas: food and beverages, animal feed, including pet food, nutritional supplements, infant nutrition, cosmetics (including nutricosmetics), medical foods and pharmaceutical and veterinary applications, among others.

Provided herein is a method for extracting polysaccharides, for example, β-glucan and sodium alginate, from a sample including a botanical product. The extraction can be carried out using a microwave assisted dual-solvent extraction followed by one or more membrane filtration steps.

The present invention is directed to a polysaccharide foil comprising a polysaccharide polymer and a plasticizer, wherein the polysaccharide polymer originates from fermentation of a bacterium or a fungus such as Ascomycota. The invention further relates to the use of the polysaccharide foil and a method for its production.

Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% β-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In at least one embodiment, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.

Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% β-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In at least one embodiment, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.

The present invention relates to a Bifidobacterium bifidum inducing regulatory T cells (Treg), a polysaccharide derived from Bifidobacterium bifidum, and a probiotic strain producing a polysaccharide and, more particularly, a polysaccharide containing β-1-6-glucan as an effective ingredient, a probiotic strain producing β-1-6-glucan, a food comprising the polysaccharide or strain as an effective ingredient for alleviation of immune disease or inflammatory disease, a therapeutic agent comprising the polysaccharide or strain as an effective ingredient for alleviation of immune disease or inflammatory disease, a method for preparing induced regulatory T cells (iTreg) by treatment with the polysaccharide or strain, and a cell therapy product for prevention or treatment of immune disease or inflammatory disease, comprising the induced regulatory T cells prepared by the method.

The presently claimed invention is directed to a method for the preparation of an aqueous solution comprising at least one beta-glucan comprising at least the steps of a) fermentation of at least one fungal strain in an a fermentation broth, b) addition of at least one acid to the fermentation broth to adjust the pH to a value in the range of ≧2.0 to ≦4.0 and c) filtration of the fermentation broth to obtain an aqueous solution comprising the at least one beta-glucan and at least one beta-glucan that is obtained by this method.

The present invention relates to a process for the fermentation of fungal strains which secrete glucans with a β-1,3-glycosidically linked main chain and side chains β-1,6-glycosidically bonded thereto, in a cascade of tanks using high-shear mixers.

The present invention relates to a composition comprising glucose oligosaccharide and a process for making such. The present invention further relates to a composition comprising glucose oligosaccharide for use in the treatment of an animal. The present invention further relates to the use of a composition comprising glucose oligosaccharide to improve the growth performance of an animal. The present invention further relates to the use of a composition comprising glucose oligosaccharide to improve the immune system modulation of an animal.